Table 3 eQTL analysis of candidate SNPs in the Finnish cohort.

From: Genetic polymorphism related to monocyte-macrophage function is associated with graft-versus-host disease

Outcome

Recipient/Donor

Gene*

SNP

CHR

A1

Risk/protective

cis-eQTL gene

Z-score

P

FDR

aGvHD

Recipient + donor

MICD

rs2523957

6

G

Risk

HLA-F

15.64

3.65 × 10–55

<0.01

       

HLA-G

−13.89

7.18 × 10−44

<0.01

       

PPP1R11

−9.09

1.03 × 10−19

<0.01

       

ZNRD1

5.44

5.27 × 10−8

<0.01

aGvHD

Recipient

PRSS53/VKRC1

rs7294

16

T

Risk

STX4

16.17

8.85 × 10−59

<0.01

       

BCKDK

−11.27

1.82 × 10−29

<0.01

       

ZNF668

−10.78

4.12 × 10−27

<0.01

       

AC093520.4, ITGAM

−6.26

3.73 × 10−10

<0.01

       

AC135050.5

−5.95

2.68 × 10−9

<0.01

       

MYST1

5.58

2.38 × 10−8

<0.01

aGvHD

Donor

IL1R1

rs3917225

2

A

Risk

IL1R2

3.36

7.73 × 10−4

0.20

aGvHD

Donor

TNF

rs1800629

6

A

Risk

TNF

−5.28

1.28 × 10−7

<0.01

       

CSNK2B

5.17

2.29 × 10−7

<0.01

       

LTA

−3.21

1.31 × 10−3

0.29

aGvHD

Donor

NFKBIA

rs2233409

14

A

Risk

cGvHD

Recipient

IL1B

rs16944

2

A

Risk

NT5DC4

3.2

1.36 × 10−3

0.30

cGvHD

Recipient

NOD2

rs6500328

16

G

Risk

NOD2

−22.76

1.10 × 10−114

<0.01

cGvHD

Donor

HSPA1L

rs2075800

6

T

Protective

CSNK2B

−22.03

1.47 × 10−107

<0.01

       

HSPA1B

20.06

1.78 × 10−89

<0.01

       

HSPA1L

8.17

3.02 × 10−16

<0.01

       

LY6G5C

5.64

1.75 × 10−8

<0.01

       

RDBP

5.62

1.90 × 10−8

<0.01

       

AIF1

5.35

8.77 × 10−8

<0.01

       

BAT3

4.52

6.13 × 10−6

<0.01

cGvHD

Donor

KRAS

rs1137282

12

G

Protective

  1. SNP indicates single nucleotide polymorphism; CHR, chromosome; A1, minor allele; eQTL indicates expressive quantitative trait loci; FDR, false detection rate; aGvHD, acute graft-versus-host disease grade III–IV; −, no cis-eQTL records found; and cGvHD, extensive chronic graft-versus-host disease.
  2. *Annotation of SNP according to National Center for Biotechnology Information dbSNP database.
  3. Risk/protective outcome status of the SNP has been determined from the association results (Table 1).
  4. Westra et al. 16. Blood eQTL Browser http://genenetwork.nl/bloodeqtlbrowser/.